Company Overview

Update
Headquarters:
New Haven, CT
Funding:
$1.20M
Categories:
Biotechnology

Axerion Therapeutics is a biotech company focused on developing innovative therapeutics for neurological diseases and injuries.

Description

Update

Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.

Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.

Current Team (2)

Update

Board Members and Advisors (1)

Update

Funding Rounds (2) - $1.20M

Update

Investors (1)

Update
  • 0a1fc8ca9464a6026e63bfd6586fdf01

    Connecticut Innovations

    Connecticut Innovations provides strategic capital and operational insight to to companies in..

Offices/Locations (1)

Update
  • Office

    555 Long Wharf Drive

    11th Floor

    New Haven, CT 06511

    USA